Domainex become first CRO to install Nuclera’s eProtein Discovery system

Domainex has become the first contract research organisation (CRO) to install Nuclera’s eProtein Discovery system and offer protein production services using the technology.

Nuclera, which raised $75m in a Series C round as reported in the Cambridge Independent last week, was founded in 2013 by Michael Chen, Jiahao Huang, and Gordon Herling-McInroy.

Its eProtein Discovery system is designed to speed up protein expression and purification optimisation in research labs, particularly those using AI including ML for protein design. The company, which is based at One Vision Park in Impington, has completed 11 installs of eProtein Discovery, including at leading academic institutes.

Chesterford Research Park-based Domainex provides a complete range of pre-clinical drug discovery services from protein production to medicinal chemistry for lead optimization. Installing eProtein Discovery expands Domainex’s service offering and enhances the company’s protein production workflows. Working with Domainex, more researchers will benefit from eProtein Discovery, supporting Nuclera’s mission to better human health by enabling scientists to easily access the proteins they need for their drug discovery research. For companies that are not yet ready or able to invest in the instrument, this provides another route to access the technology.

Joseph Bertelsen, chief commercial officer, Nuclera, said: “We are excited to have trusted protein experts like Domainex as our first CRO Partner assisting us in making eProtein Discovery accessible to scientists worldwide.

Natalie Winfield, executive vice president, commercial operations, Domainex, said: “We are delighted to be the first CRO to offer a protein production service via the eProtein Discovery system. At Domainex, we are constantly evolving our service offering, ensuring that we have the latest and most innovative technologies, so we can apply optimal approaches to our clients’ drug discovery programs.”